Maxim Group Initiates Coverage On 20/20 Biolabs with Buy Rating, Announces Price Target of $5
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Maxim Group analyst Michael Okunewitch initiates coverage on 20/20 Biolabs (NASDAQ:AIDX) with a Buy rating and announces Price Target of $5.
Maxim Group analyst Michael Okunewitch initiates coverage on 20/20 Biolabs (NASDAQ:AIDX) with a Buy rating and announces Price Target of $5.